Patient & family
resources
Living with a rare disease comes with unique challenges. We are committed not only to advancing medicines but also to providing clear, reliable information and resources to support patients and families along the way. Explore tools, educational materials, and assistance programs designed to help you navigate care with confidence.
Access to genetic testing
Mirum sponsors a genetic cholestasis panel test at no cost to patients
to help accurately identify a variety of conditions. This panel may assist
in diagnosing a cholestatic liver disease.
Complimentary Information Kits
Supporting Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) patients and families with key disease information and supportive resources.
Created in partnership with leading advocacy organizations the Alagille Syndrome Alliance and the PFIC Network.
Vitamins and supplements funds
The HealthWell Foundation, an independent U.S.-based organization, has launched two separate funds to provide financial assistance to patients living in the U.S. with ALGS and Inborn Metabolic or Genetic Bile Acid Deficiencies, including SLOS. Through the funds, which are distributed by HealthWell, eligible patients within the U.S. and U.S. territories who have insurance and annual household incomes up to 500 percent of the federal poverty level can qualify for up to $1,500 for ALGS and up to $1,000 for Inborn Metabolic or Genetic Bile Acid Deficiencies in financial assistance to obtain vitamins and supplements for the management of their condition.
Learn more about the algs vitamins and supplements fund
Inspiring community stories
Watch real stories from patients and families who are navigating the challenges of rare diseases, sharing their experiences and hope.
Patient support & access programs
Mirum Access Plus (MAP) – U.S.
Designed to help patients and families start and stay on Mirum medicines, this program connects patients and families with MAP experts who can help educate them on their journey, from treatment access to financial support.
Embrace Patient Support Program for LIVMARLI® (maralixibat) – Canada
For more information about the Embrace Patient Support Program for access in Canada, call 1-833-505-1242 or email support@mirumembrace.com.
Expanded access programs for
Mirum Medicines
Mirum’s Expanded Access Program (EAP) offers access to LIVMARLI for eligible patients with ALGS and PFIC.
- Physicians in Canada and the U.S. who are interested in the ALGS EAP should contact mirumalgs@clinigengroup.com
- Physicians in Canada and the U.S. who are interested in the PFIC EAP should contact mirumPFIC@clinigengroup.com
- Physicians outside of Canada and the U.S. who are interested in the PFIC or ALGS EAP should contact medicineaccess@clinigengroup.com
- To learn more about Mirum’s open clinical trials, please visit www.clinicaltrials.gov
Compassionate Use
Mirum may consider providing an investigational therapy to an individual patient outside of a clinical trial when an appropriate program or regulatory pathway is available.
Zilurgisertib Compassionate Use Program for FOP
A compassionate use program for investigational zilurgisertib is currently available in the United States for eligible patients 12 years of age and older with fibrodysplasia ossificans progressiva (FOP).
Mirum continues to assess potential access pathways in additional countries, as appropriate.
For licensed physicians
For information about the zilurgisertib Compassionate Use program, contact compassionateuse@mirumpharma.com
Find information and support for people and families living with rare diseases
Spectrum Disorder (PBD-ZSD)
Progress Through Clinical Studies
Advancing potential treatment options in rare disease requires close collaboration with the communities we serve. Explore our ongoing studies and learn how we are working to advance rare disease care.
